Drugs / Gam-COVID-Vac XBB
Gam-COVID-Vac XBB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06068569 | Oct 2023 → Dec 2024 | COVID-19 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gam-COVID-Vac XBB | “The Gam-COVID-Vac XBB (Sputnik V XBB) vaccine was developed, manufactured, and stored by Gamaleya NRCEM (Moscow, Russia).” PMID 41972135 ↗ Mar 2026 |
| Known as | GamCovidVac | “GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)” NCT06068569 ↗ |
| Known as | Sputnik V XBB | “The Gam-COVID-Vac XBB (Sputnik V XBB) vaccine was developed, manufactured, and stored by Gamaleya NRCEM (Moscow, Russia).” PMID 41972135 ↗ Mar 2026 |
| Modality | Vaccine | “GamCovidVac vector vaccine” NCT06068569 ↗ |
| Route | Intramuscular | “Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed.” NCT06068569 ↗ |